Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Recruiting

Phase 3

Deucravacitinib vs. UstekinumabLong-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Sponsor:

Bristol-Myers Squibb

Code:

NCT07116967

Conditions

Plaque Psoriasis

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Interventions

Deucravacitinib

Ustekinumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-03. This information was provided to ClinicalTrials.gov by Bristol-Myers Squibb on 2026-03-02.